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Background: Severe exacerbations and mortality are major outcomes in COPD, and risk factors 
for these events are actively searched for. Several predictors of mortality have been identified 
in COPD. The inspiratory capacity/total lung capacity (IC/TLC) ratio has been shown to be a 
strong predictor of all cause and respiratory mortality in patients with COPD. The major objec-
tives of this study were to analyze which clinical parameters, including lung volumes, were the 
best predictors of the 5-year cumulative risk of hospital admissions or death and the 5-year risk 
of exacerbations, in stable COPD patients.
Methods: This study retrospectively reviewed data from 98 stable COPD patients, consecu-
tively recruited in 2012. Forced expiratory volume in 1 s (FEV
1
), modified Medical Research 
Council dyspnea scale, exacerbation history (ExH), Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) 2011 groups, and lung volumes were reviewed. Five years later, this 
population was evaluated for cumulative exacerbations, hospital admissions, and mortality. 
All the population, and GOLD group D separately, were analyzed.
Results: The cumulative 5-year combined risk of hospital admission or death was significantly 
predicted by the ExH and the IC/TLC ratio. Analyzing separately group D, FEV
1
 was the 
only predictor of this outcome. The frequency of exacerbations in the previous year was the 
best predictor of future cumulative 5-year risk of subsequent exacerbations, both for the total 
population and the GOLD D group.
Conclusion: ExH and IC/TLC ratio were the best predictors of the most severe outcomes in 
COPD (admissions or mortality), independently of COPD severity. FEV
1
 was the only predictor 
of the cumulative 5-year combined risk of hospital admission or death in the GOLD D group. 
ExH was the best predictor of 5-year cumulative future risk of exacerbations. Besides FEV
1
 and 
ExH, the IC/TLC ratio can be a useful predictor of severe outcomes in COPD.
Keywords: FEV
1
, severe outcomes, admissions, mortality, IC/TLC ratio
Introduction
The prognosis of COPD is a major concern in the present management of the disease, 
as it is a significant cause of mortality1 and estimated to be increasing.2–5 COPD is 
the 4th leading cause of death worldwide, and it is estimated that, by 2020, it will be 
the 3rd leading cause.6
Identifying high risk patients and the factors that can best predict the worse out-
comes, severe exacerbations with hospital admissions and risk of death, are major 
objectives that should be applied in clinical practice.5
COPD is a complex and heterogeneous disease, and several factors are related 
to adverse events. Exacerbations are major risk factors for progression of disease,7 
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significant worsening of symptoms,8 exercise capacity,8 
poor quality-of-life,9 and mortality.10 Severe exacerbations 
resulting in hospital admissions have significant in-hospital 
mortality.11,12 Survival after admission is poor and related to 
the number of previous severe exacerbations.11,13,14
The prognosis of COPD is highly related to the severity 
and frequency of acute exacerbations, especially with the 
severe ones that result in hospital admission.11,15 Both severe 
exacerbations and mortality are major outcomes in COPD, 
and risk factors for these events are actively searched for in 
order to modify the course of the disease.16
Several predictors of mortality in COPD have been 
identified: forced expiratory volume in 1 s (FEV
1
), age, body 
mass index (BMI), dyspnea, exercise capacity, exacerbation 
frequency, previous severe exacerbations, BODE index, and 
the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) classes.17–23
The mortality predictive capacity of the GOLD 2011 
classification has been compared to the previous stratifica-
tion using FEV
1
 severity, and it has been demonstrated that 




Lung function studies in COPD are mainly derived from 
spirometry, and FEV
1
 is a powerful marker of the severity, 
progression of the disease, and risk of mortality.18,21,24 How-
ever, FEV
1
 is poorly correlated with clinical variables such 
as symptoms or exacerbations.
Other lung function variables (such as lung volumes, 
diffusing capacity for carbon monoxide [DLCO], exercise 
capacity, blood gases, or presence of respiratory insuffi-
ciency) are known to represent useful parameters that can 
help to understand the physiopathology of dyspnea, exercise 
limitation, and hypoxemia. These tests are recommended in 
certain circumstances, but are not usually used as predic-
tors for adverse events in conjunction with other clinical 
dimensions.16
It is known that the inspiratory capacity/total lung 
capacity (IC/TLC) ratio, that represents the static hyper-
inflation, sometimes designated as the inspiratory frac-
tion, is highly related to dyspnea and exercise capacity, 
as it is worsened in exercise (dynamic hyperinflation).25,26 
Several studies have concluded that this ratio can be very 
useful in understanding clinical effects (dyspnea,27 exercise 
capacity limitation,28 muscular weakness,29 and eventually 
exacerbations30,31) and can be used as a strong predictor of 
all cause and respiratory mortality in COPD patients.25,32,33 
However, these findings have not been applied in recom-
mendations and clinical practice.
The major objectives of this study were to analyze which 
clinical parameters, including lung volumes determination, 
and the IC/TLC ratio in particular, were the best predictors of 
the 5-year cumulative risk of hospital admissions or death and 
the 5-year risk of exacerbations, in stable COPD patients.
Methods
Design and population
We used in this study a previous sample of 100 patients with 
COPD followed at the ambulatory Pulmonary Clinic of Hos-
pital de Santa Marta, Lisbon, Portugal. Stable COPD patients 
were consecutively recruited between January and February 
2012, in order to compare their different classification by the 
GOLD 2011 versus the previous GOLD 2007. Patients had 
a clinical diagnosis of COPD confirmed by a post broncho-
dilator forced expiratory volume in 1 s/forced vital capacity 
(FEV
1
/FVC),0.70. Patients were in a stable state, and with no 
exacerbations in the previous 3 months. At that time, patients 
with a history of asthma, other associated lung conditions, 
previous lung surgery, lung cancer, or significant and unstable 
cardiac condition were excluded. This sample was classified 
according to the ABCD of GOLD 2011 (FEV
1
, modified 
Medical Research Council [mMRC] dyspnea scale, previous 
year exacerbations), and all patients performed spirometry and 
lung volume determination by plethysmography by the same 
respiratory technicians. Not all patients had a DLCO or blood 
gases determination, so we excluded these parameters of the 
analysis. All lung function variables analyzed are postbroncho-
dilator. Respiratory function tests were performed according to 
ATS/ERS (American Thoracic Society/European Respiratory 
Society) recommendations,34,35 and the European Community 
for Steel and Coal/ERS reference values were used.36
The study involved a 5-year retrospective review of 
patients who presented to the Pulmonary Clinic of the Hospital. 
Of this sample of 100 patients, 98 patients were included in 
this study, as two patients had no lung volume determination. 
Patients were considered alive if they had a regular follow-up 
in the first 4 months of 2017. Death of patients was confirmed 
by consulting our records or the national registry. The all-
cause mortality is used in this study, as the cause of death 
was not possible to identify in all patients.
Data collection and follow-up
Data were collected by the authors from the clinical files, and 
admission and discharge records. Data collected included 
baseline demographic data, respiratory function assess-
ments, and previous exacerbations. Patients were categorized 
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Predictors of severe outcomes in COPD
or D (GOLD A – FEV
1
$50%, mMRC,2, Exacerbations,2; 
GOLD B – FEV
1
$50%, mMRC$2, Exacerbations,2; 
GOLD C – FEV
1
,50%, mMRC,2, Exacerbations$2; 
GOLD D – FEV
1
,50%, mMRC$2, Exacerbations$2).37
Follow-up extended until 60 months (5 years) after the 
initial baseline data collection. Hospitalizations, exacerba-
tions, and deaths were collected from the clinical files, and 
admission and discharge records. We analyzed the total 
population and the GOLD D group separately.
Outcomes
The primary composite outcome was death or admissions 
from the baseline data collection until 60 months. The 
secondary outcome was exacerbations from the baseline 
data collection until 60 months.
statistical analysis
All categorical variables were expressed as numbers or 
percentages. All continuous variables were expressed using 
median and minimum–maximum. Between group analysis 
was performed using the Mann–Whitney U-test or the χ2 test, 
respectively, for continuous and discrete variables. Explor-
atory univariate analyses were performed, followed by 
multivariate regression analyses. Variables selected for the 
multivariate analyses were those with an α,0.05 (two-sided) 
on univariate analyses. Variables were selected using the 
backward step elimination. The Bonferroni correction was 
applied to both univariate and multivariate analyses when 
necessary. Tests were considered significant at α=0.05 sig-
nificance level (two-sided). SPSS v20 was used for statistical 
analysis.
ethics committee approval
This study was approved by the Institutional Review 
Board of Hospital de Santa Marta, CHLC. The need for 
written informed consent from all participants was waived 
because this was a retrospective study with anonymized 
patient data.
Results
Baseline values by gOlD group
There were several significant differences on baseline 
parameters between the GOLD groups (Table 1 and 
Figures 1–4).
Forty-nine percent of patients were classified as group D, 
and 70% as groups B and D. Groups C and D had higher 
than normal static lung volumes, consistent with the pres-
ence of hyperinflation and emphysema (total lung capacity, 
intrathoracic gas volume, residual volume). Interestingly, 
group D had a significantly lower IC than group C (Table 1). 
FEV
1
 declined across groups, being worse in group D. There 
was no difference between groups A and B (Figure 1). The 
mMRC was significantly higher in group D compared to 
group B (Figure 2). All lung function parameters showed 
differences between GOLD groups. Previous year exacer-
bations were lower than two in group C, which means that 
these patients were mainly classified by their lung function 
severity. Group D had more than two exacerbations, on 
average (Figure 3). IC/TLC (%) also declined across groups, 
being worse in group D. There was no difference between 
groups A and B (Figure 4).
Comparison of variables at baseline and 
outcomes at 5 years by gOlD group
Table 2 shows the comparison of variables at baseline and 
outcomes at 5 years by GOLD group. Almost 70% of GOLD C 
patients and almost 90% of GOLD D patients experienced 
exacerbations during the 5-year follow-up. There were 
24 deaths during follow-up, 67% of which were in group D, 
meaning that the death rate in the other three groups was 
33%. There were 53 admissions during follow-up, 67.3% 
Table 1 Baseline characteristics by gOlD 2011 group
Parameter A (n=16) B (n=21) C (n=13) D (n=48)
age (years) 63.0 (49.0–80.0) 65.0 (49.0–80.0) 70.0 (49.0–74.0) 67.0 (44.0–80.0)
Female, n (%) 1 (6.2) 7 (33.3) 1 (7.7) 6 (12.5)
IC (%) 110.5 (76.0–143.0)a,c 106.0 (47.0–161.0)b 96.0 (51.0–115.0)c 72.0 (31.0–141.0)
FeV1/FVC 65.9 (36.0–79.9)
a 56.5 (38.1–79.6)b 38.5 (27.5–69.9) 35.1 (23.1–63.9)
TlC (%) 110.0 (75.0–135.0) 108.0 (63.0–157.0)c 126.0 (95.0–141.0)c 123.0 (61.0–184.0)
ITgV (%) 109.5 (74.0–167.0)a 114.0 (78.0–187.0)b 173.0 (100.0–189.0) 164.0 (73.0–294.0)
rV (%) 110.5 (42.0–158.0)a 121.0 (70.0–191.0)b 183.0 (121.0–216.0) 197.5 (65.0–437.0)
Notes: all measures taken postbronchodilation. all values, except gender, presented as median (minimum–maximum). The predicted values used for lung function are the 
eCsC/ers equations.36 GOLD 2011 groups defined in the “Data collection and follow-up” section. aP,0.001 a vs C/D; bP,0.001 B vs C/D; cP=0.005.
Abbreviations: eCsC, european Community for steel and Coal; gOlD, global Initiative for Chronic Obstructive lung Disease; IC, inspiratory capacity; FeV1, forced 
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Figure 1 Baseline FeV1 between gOlD groups. 
Notes: *P,0.01; **P,0.001. GOLD 2011 groups defined in the “Data collection and follow-up” section.
Abbreviations: FeV1, forced expiratory volume in 1 s; gOlD, global Initiative for Chronic Obstructive lung Disease.
Figure 2 Baseline mMrC between gOlD groups. 
Notes: *P,0.01; **P,0.001. GOLD 2011 groups defined in the “Data collection and follow-up” section.
Abbreviations: mMRC, modified Medical Research Council; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
of which were in group D, which was statistically different 
from the other three groups combined (32.7%, P,0.001). 
Exacerbations in the previous year, IC/TLC post,25%, death 
or admission after 5 years, and exacerbations after 5 years 
were all different when comparing GOLD A and GOLD D 
patients. We analyzed the IC/TLC ratio in two groups, those 
with a ratio lower than 25% versus those higher than 25%, as 
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Predictors of severe outcomes in COPD
Figure 3 exacerbations in the previous year between gOlD groups. 
Notes: *P,0.01; **P,0.001. GOLD 2011 groups defined in the “Data collection and follow-up” section.
Abbreviation: gOlD, global Initiative for Chronic Obstructive lung Disease.
Figure 4 Baseline IC/TlC between gOlD groups. 
Notes: *P,0.001. GOLD 2011 groups defined in the “Data collection and follow-up” section.
Abbreviations: IC/TlC, inspiratory capacity/total lung capacity; gOlD, global Initiative for Chronic Obstructive lung Disease.
This ratio was above 25% in almost all group A and B 
patients, and lower than 25% in 46% and 40% of groups C 
and D, respectively, with no statistical difference between 
these latter two groups.
Primary outcome (death or admission)
The cumulative 5-year combined risk of hospital admission 
or death was significantly predicted by the exacerbation 
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(Table 3). Dyspnea (mMRC), FEV
1
, and other lung volumes 
did not predict this outcome. Analyzing group D separately, 
of the most severe and high risk patients, FEV
1
 was the only 
predictor of this outcome.
secondary outcome
The frequency of exacerbations in the previous year was the 
best predictor of future cumulative 5-year risk of subsequent 
exacerbations, both for the total population and for the 
GOLD D group (Table 3). No other parameter had signifi-
cance concerning this outcome.
Discussion
We found in our study that ExH and IC/TLC ratio were the 
best predictors of the most severe outcomes in COPD (admis-
sions or mortality), and they can be applied to all COPD 
patients independently of their severity. FEV
1
 was the only 
predictor of the cumulative 5-year combined risk of hospital 
admission or death in GOLD D COPD patients. ExH was the 
best predictor of 5-year cumulative future risk of exacerba-
tions in the whole population sample. To our knowledge, 
this is the first study to analyze the 5-year prediction of the 
combination of exacerbations, hospital admissions, and 
mortality in stable COPD patients.
Major factors for a poor outcome in COPD are severe 
exacerbations and risk of mortality. Current knowledge con-
siders that FEV
1
, dyspnea severity, exacerbations frequency 
and severity, and GOLD classes are good predictors of 
progression of COPD and risk of mortality.5 These variables 
can be easily obtained in a clinical setting when predicting 
future risk and can be important in order to offer the best 
treatment available to reduce risk of severe exacerbations 
with hospital admissions and mortality. Complementary 
parameters have been investigated to better predict these 
risks in the most severe patients and at high risk of worse 
outcomes. The previous year exacerbation frequency and 
severity is considered to be the best predictor of future risk 
of exacerbations,20 but this does not have the discriminative 
capacity to identify which patients will be at risk of a severe 
exacerbation and hospital admission and risk of mortality.
These were the major objectives of our study: identifying 
which parameters easily obtained in clinical practice can 
be predictors of the combined risk of hospital admissions 
or death and exacerbations. With this study, we tried to 
simulate the usual clinical context in the management of 
COPD patients. Most importantly, we tried to identify risk 
factors that can be used in stable COPD patients, followed 
in an ambulatory setting that can predict future major events 
besides the accepted important role of FEV
1
, dyspnea 
severity, and previous exacerbations.
The future risk of exacerbations has been considered to be 
best predicted by the frequency and severity of exacerbations 
in the previous year.20 Besides FEV
1
, the role of other lung 
function tests is less clear, the exception being the IC/TLC 
ratio.25,32,33 This ratio is very well correlated with dyspnea, 
as it represents static hyperinflation that worsens on exercise 
(dynamic hyperinflation resulting in exercise limitation caused 
by exercise dyspnea), such as in emphysema.26 This ratio can 
also be associated with more frequent exacerbations,31 risk 
of severe ones, and risk of death.25,32,33
Table 2 Comparison of variables at baseline and outcomes at 
5 years by gOlD 2011 group
Parameter A (n=16) B (n=21) C (n=13) D (n=48)
ex previous year 0 (0.0)a,b 9 (42.9)c,d 12 (92.3) 42 (87.5)c,d
IC/TlC,25% 0 (0.0)e 1 (4.8)d  6 (46.2) 19 (39.6)d,e
D or a after 5 years 3 (18.8)a 6 (28.6)d  8 (61.5) 35 (72.9)d
ex after 5 years 9 (56.2)b 5 (23.8)c  9 (69.2) 43 (89.6)c
Notes: IC/TlC measures taken post-bronchodilation. all values presented as n 
(%). GOLD 2011 groups defined in the “Data collection and follow-up” section. 
aP,0.001 a vs C/D; bP,0.01 a vs B/D; cP,0.001; dP,0.01; eP,0.01.
Abbreviations: gOlD, global Initiative for Chronic Obstructive lung Disease; 
ex, exacerbations; IC/TlC, inspiratory capacity/total lung capacity; D or a, death 
or admission.
Table 3 Predictors of death or readmission after 5 years and of exacerbations after 5 years on multivariate analyses
Subgroup/predictor(s) Death or readmission after 5 years Exacerbations after 5 years
B Exp (B) 95% CI for Exp (B) P-value B Exp (B) 95% CI for Exp (B) P-value
gOlD D 2011 group
age (years) 0.122 1.130 0.998–1.279 0.054 0.125 1.133 0.858–1.495 0.379
FeV1 (%) -0.215 0.807 0.680–0.957 0.014 0.042 1.043 0.764–1.422 0.793
exacerbations in previous year (n) 1.860 6.423 0.978–42.179 0.053 4.232 68.855 17.364–273.039 ,0.001
Total population
age (years) 0.052 1.053 0.992–1.118 0.090 0.003 1.003 0.863–1.165 0.973
IC/TlC (%) -10.465 0.000 0.000–0.023 0.002 11.203 7.3×104 2.4×10-5–2.3×1014 0.315
exacerbations in previous year (n) 0.817 2.263 1.189–4.306 0.013 4.010 55.120 19.216–158.103 ,0.001
Note: GOLD D 2011 group defined in the “Data collection and follow-up” section.
Abbreviations: gOlD, global Initiative for Chronic Obstructive lung Disease; FeV1, forced expiratory volume in 1 s; IC/TlC, inspiratory capacity/total lung capacity; 
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Predictors of severe outcomes in COPD
Other studies have proved the importance of this ratio and 
of the static hyperinflation. The NETT Trial has demonstrated 
that surgical lung volume reduction reduces the frequency 
of COPD exacerbations and mortality in selected cases of 
emphysema,22 and the study by French et al32 also concluded 
that the IC/TLC ratio is a good predictor of mortality in 
emphysema. However, these studies did not compare the 
value of different important baseline clinical parameters, 
such as FEV
1
, dyspnea, and ExH, or the GOLD group, 
with lung volumes, neither did they evaluate which of these 
parameters would be more predictive of 5-year cumulative 
exacerbations or the combined 5-year risk of admission 
(severe exacerbation) or death.
Findings in univariate analysis
All lung function parameters showed differences between 
GOLD A and GOLD D patients. Baseline IC/TLC did not 
differ between GOLD A and GOLD B patients, although 
exacerbations after 5 years were higher in the GOLD A group 
compared to the GOLD B group (56.2% vs 23.8%, P,0.01). 
The latter result was unexpected and may be related to non-
compliance or undertreatment of GOLD A patients.
Findings in multivariate analysis
Our finding that exacerbations in the previous year are the 
strongest predictor of future exacerbations is in line with 
previous findings20 and the GOLD guidelines.5
The cumulative 5-year combined risk of hospital 
admission or death was significantly predicted by the 
ExH and the IC/TLC ratio for the total population. In our 
opinion, ExH and the IC/TLC ratio should be used more 
often in clinical practice, even in the less severe patients, 
reinforcing the extreme value of previous exacerbations, 
independent of their phenotype (which was not analyzed 
in our study). Our findings identify IC/TLC as another 
possible respiratory function parameter of the worse out-
comes in COPD.
We think that determination of IC/TLC by plethysmog-
raphy, even if not available in all heath care settings as 
spirometry, can be a useful parameter to identify patients 
with worse outcomes. Baseline determination of IC/TLC, 
conjugated with FEV
1
, mMRC, and ExH, can be a powerful 
tool to identify high risk patients. In patients with progres-
sive disease, clinical and functional worsening, repeated IC/
TLC determination would be helpful in evaluating treatment 
response.
If only the GOLD D group (half of patients in the 
sample) was analyzed, FEV
1
 was the only predictor of 
cumulative 5-year combined risk of hospital admission 
or death. The suggestion that these patients can be 
extremely important in the management of COPD is 
somehow implicit in the recent GOLD 2017 revision (even 
though FEV
1
 is no longer included in the classification),5 
in a recent proposal of the CERO index by Celli et al38 (a 
composite index of major outcomes using admissions and 
mortality, to use in clinical studies, as was our case), and 
also in the recent Spanish GesEPOC guidelines, 2017 revi-
sion39 that considers that these patients, GOLD D, are high 
risk patients. It is our opinion that the lack of prediction 
of exacerbations and IC/TLC in the separate multivariate 
analysis of the GOLD D group may be related to the small 
number of patients.
strengths and limitations
Some of the strengths of this study are the fact that all patients 
were treated according to the GOLD 2011 guidelines,37 by 
the same physicians, lung function testing were obtained 
by the same technicians, and all patients were included in 
a stable state (no exacerbations in the previous 3 months). 
Even in the context of a small sample, some variables, 
such as previous exacerbation frequency and IC/TLC ratio, 
were significantly associated with the defined outcomes in 
univariate and multivariate statistical analysis. This finding 
is very important, as it can be extremely useful to apply in 
clinical practice, given the small number of patients neces-
sary to have a significant predictor capacity of the major 
outcomes. Moreover, these parameters are applicable to all 
GOLD groups of COPD patients, and, therefore, can be valid 
in a general clinical context, and not in a specific or special 
population (emphysematous phenotype or previous severe 
exacerbations only).22,32
The major limitations of this study include its retro-
spective design, the fact that the population studied was 
followed in a secondary respiratory outpatient clinic, the 
small sample size (although homogeneous during the time 
frame of inclusion), being a single center study, and the 
non-inclusion in the analyses of DLCO, blood gases, and 
exercise capacity, due to the fact that they have not been 
performed in all patients.
Conclusion
We found that ExH and IC/TLC ratio were the best predic-
tors of the most severe outcomes in COPD (admissions or 
mortality), and that they can be applied to all COPD patients 
independently of their severity. In this study, FEV
1
 was the 
only predictor of the cumulative 5-year combined risk of 
hospital admission or death in high risk COPD patients: 
FEV
1
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ExH was the best predictor of 5 years cumulative future risk 
of exacerbations. Besides FEV
1
, mMRC, and ExH, which 
usually classify severity and risk in COPD patients, we 
think that IC/TLC ratio can be a complementary parameter 
to predict severe outcomes in COPD.
Disclosure
The authors report no conflicts of interest in this work.
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